Karyopharm Therapeutics | KPTI - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 15B 1.62B 2026-03
Abbott USD 11.16B 300M 2026-03
Amgen USD 8.62B 1.28B 2026-03
AstraZeneca USD 15.29B 213M 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
GlaxoSmithKline GBP 7.63B 991M 2026-03
Incyte USD 1.27B 240M 2026-03
J&J USD 24.1B 500M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.29B 110M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Novartis USD 13.11B 226M 2026-03
Novartis USD 13.11B 750M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Takeda JPY 1.09T 100B 2026-03
Tectonic Therapeutic USD 0 0 2024-12
TG Therapeutics USD 194.8M 2.23M 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Xencor USD 4.51M 23.73M 2026-03